Edgeline Holdings acquires patent rights from Pharmaceutical Research Institute

Edgeline Holdings, a biopharmaceutical firm of the US, has agreed to terms for an exclusive worldwide right to option patents covering the composition and use of Genistein analogs for cancer treatment. The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw, Poland and involves compounds that appear to be novel antimicrotubule agents.

Given the widespread success of antimicrotubule therapies in curative and palliative cancer treatment, the microtubule is perhaps the single best cancer target identified to date and continues to be recognised as a strategic target against which to direct new development efforts.

Source : www.polishmarket.com